Oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer

dc.contributor.author Sendogan, Furkan
dc.contributor.author Turan, Turgay
dc.contributor.author Keser, Ferhat
dc.contributor.author Hancilar, Tayfun
dc.contributor.author Atis, Gokhan
dc.contributor.author Yildirim, Asif
dc.date.accessioned 2024-05-25T11:38:12Z
dc.date.available 2024-05-25T11:38:12Z
dc.date.issued 2023
dc.description Keser, Ferhat/0000-0002-2803-6481 en_US
dc.description.abstract Introduction The aim of this study was to compare the long-term oncological results of patients with the diagnosis of prostate cancer who underwent open radical retropubic prostatectomy (RRP) and subse-quent adjuvant (ART) or salvage radiotherapy (SRT).Material and methods A total of 145 patients underwent open RRP for prostate cancer and subsequent ART or SRT postoperatively between 2010 and 2019. ART (n = 56) is defined as the group of patients with prostate-specific antigen (PSA) <0.2 ng/mL or with positive lymph nodes without PSA increase who re-ceived radiotherapy within the first 6 months of urinary continence. SRT (n = 89) is defined as the group of patients with PSA >0.2 ng/mL who received RT before PSA amounted to 0.5 ng/mL.Results Statistically no significant difference was found between groups in terms of age, prostate volume, final pathology Gleason scores, lymphadenectomy, duration of androgen deprivation therapy (ADT), time to relapse after radiotherapy, development of biochemical recurrence and disease progression. Extraprostatic extension, seminal vesicle invasion and surgical margin positivity were significantly higher in the ART group. No difference was found between the groups in terms of biochemical recurrence-free survival, while cancer-specific survival and overall survival rates were significantly higher in the SRT group.Conclusions It was found that cancer-specific and overall survival was better in the SRT group. It will be more appropriate to follow-up until the recurrence and then to perform SRT after the relapse in the postoperative period. en_US
dc.identifier.citationcount 0
dc.identifier.doi 10.5173/ceju.2023.190
dc.identifier.issn 2080-4806
dc.identifier.issn 2080-4873
dc.identifier.scopus 2-s2.0-85164591751
dc.identifier.uri https://doi.org/10.5173/ceju.2023.190
dc.identifier.uri https://hdl.handle.net/20.500.14517/1252
dc.language.iso en
dc.publisher Polish Urological Assoc en_US
dc.rights info:eu-repo/semantics/openAccess en_US
dc.subject prostate cancer en_US
dc.subject biochemical recurrence en_US
dc.subject adjuvant radiotherapy en_US
dc.subject salvage radiotherapy en_US
dc.title Oncologic outcomes of postoperative adjuvant versus salvage radiotherapy in prostate cancer en_US
dc.type Article en_US
dspace.entity.type Publication
gdc.author.id Keser, Ferhat/0000-0002-2803-6481
gdc.author.institutional Yildirim A.
gdc.author.scopusid 56916074500
gdc.author.scopusid 42162301800
gdc.author.scopusid 57211282443
gdc.author.scopusid 16303886500
gdc.author.scopusid 26424996000
gdc.author.scopusid 23098715100
gdc.author.wosid Keser, Ferhat/ABB-5163-2021
gdc.coar.access open access
gdc.coar.type text::journal::journal article
gdc.description.department Okan University en_US
gdc.description.departmenttemp [Sendogan, Furkan] Sisli Mem Hosp, Dept Urol, Istanbul, Turkiye; [Turan, Turgay] Turgutlu State Hosp, Dept Urol, Manisa, Turkiye; [Keser, Ferhat; Atis, Gokhan; Yildirim, Asif] Istanbul Medeniyet Univ, Dept Urol, Istanbul, Turkiye; [Hancilar, Tayfun] Istanbul Okan Univ, Dept Radiat Oncol, Istanbul, Turkiye en_US
gdc.description.publicationcategory Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı en_US
gdc.description.scopusquality Q3
gdc.description.wosquality Q3
gdc.identifier.pmid 37483851
gdc.identifier.wos WOS:000966798400001
gdc.index.type WoS
gdc.index.type Scopus
gdc.index.type PubMed
gdc.scopus.citedcount 0
gdc.wos.citedcount 0

Files